| [1] |
李涌平，韩丽媛．流行病学转变视角下中国死亡水平及死因构成分析：2009-2013[J]．人口与发展，2016，22(3):36-42.
|
| [2] |
Mukai M, Komori K, Oka T．Mechanism and management of cancer chemotherapy-induced atherosclerosis[J]．J Atheroscler Thromb，2018，25(10):994-1002.
|
| [3] |
钟久昌．肿瘤心脏病学科的过去、现在与将来—机遇和挑战[J]．药学进展，2018，42(7):481-482.
|
| [4] |
Zamorano JL, Lancellotti P, Muñoz DR，et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines[J]．Kardiol Pol，2016，74(11):1193-1233.
|
| [5] |
Koutsoukis A, Ntalianis A, Repasos E，et al.Cardio-oncology：a focus on cardiotoxicity[J]．Eur Cardiol，2018，13(1):64-69.
|
| [6] |
Suter TM, Ewer MS.Cancer drugs and the heart：importance and management[J]．Eur Heart J，2013，34(15):1102-1111.
|
| [7] |
Corremans R, Adão R, De Keulenaer GW，et al.Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity[J]．Clin Exp Pharmacol Physiol，2019，46(3):204-215.
|
| [8] |
McGowan JV, Chung R, Maulik A，et al.Anthracycline chemotherapy and cardiotoxicity[J]．Cardiovasc Drugs Ther，2017，31(1):63-75.
|
| [9] |
Hanahan D, Weinberg Robert A．Hallmarks of Cancer：the next generation[J]．Cell，2011，144(5):646-674.
|
| [10] |
Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy[J]．NPJ Precis Oncol，2018(2):13.
|
| [11] |
Takada M, Yasui T, Oka T, et al. Aortic dissection and cardiac dysfunction emerged coincidentally during the long-term treatment with angiogenesis inhibitors for metastatic renal cell carcinoma[J]．Int Heart J，2018，59(5):1174-1179.
|
| [12] |
Nabialek-Trojanowska I, Lewicka E, Wrona A，et al.Cardiovascular complications after radiotherapy[J]．Cardiol J，2018.[Epub ahead of print]
|
| [13] |
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer[J]．N Engl J Med，2013，368(11):987-998.
|
| [14] |
Menezes KM, Wang H, Hada M，et al.Radiation matters of the heart：a mini review[J]．Front Cardiovasc Med，2018(5):83.
|
| [15] |
van den Bogaard VA, Ta BD, van der Schaaf A，et al.Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures[J]．J Clin Oncol，2017，35(11):1171-1178.
|
| [16] |
Zhu Q, Kirova YM, Cao L, et al. Cardiotoxicity associated with radiotherapy in breast cancer：a question-based review with current literatures[J]．Cancer Treat Rev，2018(68):9-15.
|
| [17] |
Mehta LS, Watson KE, Barac A，et al.Cardiovascular disease and breast cancer：where these entities intersect：a scientific statement from the american heart association[J]．Circulation，2018，137(8):e30-e66.
|
| [18] |
Ichikawa Y, Ghanefar M, Bayeva M，et al.Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation[J]．J Clin Invest，2014，124(2):617-630.
|
| [19] |
Levick SP, Soto-Pantoja DR, Bi J, et al. Doxorubicin-induced myocardial fibrosis involves the neurokinin-1 receptor and direct effects on cardiac fibroblasts[J]．Heart Lung Circ，2018.[Epub ahead of print]
|
| [20] |
Mohan N, Jiang J, Dokmanovic M, et al.Trastuzumab-mediated cardiotoxicity：current understanding，challenges，and frontiers[J]．Antibody Therapeutics，2018，1(1):13-17.
|
| [21] |
Costa I, Hajjar LA.What is the role of two-dimensional speckle tracking echocardiography in the diagnosis and management of anthracycline-induced cardiotoxicity？[J]．Arq Bras Cardiol，2018，110(3):229-230.
|
| [22] |
宋飞艳，程蕾蕾，陈永乐．实时三维超声心动图评价淋巴瘤患者蒽环类药物化疗后左心室亚临床功能的价值[J/CD]．中华诊断学电子杂志，2015，3(3):155-158.
|
| [23] |
Laufer-Perl M, Derakhshesh M, Milwidsky A，et al.Usefulness of global longitudinal strain for early identification of subclinical left ventricular dysfunction in patients with active cancer[J]．Am J Cardiol，2018，122(10):1784-1789.
|
| [24] |
Simões R, Silva LM, Cruz ALVM，et al.Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy：a narrative review[J]．Biomed Pharmacother，2018(107):989-996.
|
| [25] |
Menna P, Salvatorelli E．Primary prevention strategies for anthracycline cardiotoxicity：a brief overview[J]．Chemotherapy，2017，62(3):159-168.
|
| [26] |
Janbabai G, Nabati M, Faghihinia M，et al.Effect of enalapril on preventing anthracycline-induced cardiomyopathy[J]．Cardiovasc Toxicol，2017，17(2):130-139.
|
| [27] |
Chotenimitkhun R, D′Agostino R Jr, Lawrence JA，et al.Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function[J]．Can J Cardiol，2015，31(3):302-307.
|
| [28] |
Kaya MG, Ozkan M, Gunebakmaz O，et al.Protective effects of nebivolol against anthracycline-induced cardiomyopathy：a randomized control study[J]．Int J Cardiol，2013，167(5):2306-2310.
|
| [29] |
Franco YL, Vaidya TR, Ait-Oudhia S. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer[J]．Breast Cancer (Dove Med Press)，2018(10):131-141.
|
| [30] |
Veena RK, Ajith TA, Janardhanan KK.Lingzhi or Reishi medicinal mushroom，ganoderma iucidum (agaricomycetes)，prevents doxorubicin-induced cardiotoxicity in rats[J]．Int J Med Mushrooms，2018，20(8):761-774.
|
| [31] |
Song R, Yang Y, Lei H，et al.HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving alpha-tubulin acetylation[J]．J Mol Cell Cardiol，2018(124):58-69.
|
| [32] |
Kheiri B, Abdalla A, Osman M，et al.Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity[J]．Am J Cardiol，2018，122(11):1959-1964.
|
| [33] |
Piroth MD, Baumann R, Budach W，et al.Heart toxicity from breast cancer radiotherapy：current findings，assessment，and prevention[J]．Strahlenther Onkol，2019，195(1):1-12.
|